Literature DB >> 21189337

Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy.

Ryan K Shields1, Cornelius J Clancy, Aniket Vadnerkar, Eun J Kwak, Fernanda P Silveira, Rima C Abdel Massih, Joseph M Pilewski, Maria Crespo, Yoshiya Toyoda, Jay K Bhama, Christian Bermudez, M Hong Nguyen.   

Abstract

Fifty-six serum posaconazole trough levels were measured in 17 cardiothoracic transplant recipients. Initial levels were ≤ 0.5, 0.51 to 0.99, and ≥ 1 μg/ml for 47, 29, and 24% of patients, respectively. Median trough levels associated with therapeutic success were higher than those associated with failure (1.55 versus 0.34 μg/ml; P = 0.006). Patients with levels consistently >0.5 μg/ml were more likely to have successful outcome (P = 0.055). Age ≥ 65 years, oral administration, and absence of proton pump inhibitors were associated with higher levels of posaconazole (P = 0.006, 0.006, and 0.001, respectively).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21189337      PMCID: PMC3067082          DOI: 10.1128/AAC.01325-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Nocturnal weakly acidic reflux promotes aspiration of bile acids in lung transplant recipients.

Authors:  Kathleen Blondeau; Veerle Mertens; Bart A Vanaudenaerde; Geert M Verleden; Dirk E Van Raemdonck; Daniel Sifrim; Lieven J Dupont
Journal:  J Heart Lung Transplant       Date:  2009-02       Impact factor: 10.247

Review 2.  Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.

Authors:  Brahm H Segal; Raoul Herbrecht; David A Stevens; Luis Ostrosky-Zeichner; Jack Sobel; Claudio Viscoli; Thomas J Walsh; Johan Maertens; Thomas F Patterson; John R Perfect; Bertrand Dupont; John R Wingard; Thierry Calandra; Carol A Kauffman; John R Graybill; Lindsey R Baden; Peter G Pappas; John E Bennett; Dimitrios P Kontoyiannis; Catherine Cordonnier; Maria Anna Viviani; Jacques Bille; Nikolaos G Almyroudis; L Joseph Wheat; Wolfgang Graninger; Eric J Bow; Steven M Holland; Bart-Jan Kullberg; William E Dismukes; Ben E De Pauw
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 9.079

Review 3.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

4.  Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.

Authors:  Cornelius J Clancy; Victor L Yu; Arthur J Morris; David R Snydman; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

Authors:  Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

6.  A computerized surveillance system for disease outbreaks in Oklahoma.

Authors:  S Lanser; S J McNabb; J M Horan
Journal:  Am J Public Health       Date:  1994-12       Impact factor: 9.308

7.  Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.

Authors:  Drew J Winston; Kathy Bartoni; Mary C Territo; Gary J Schiller
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-09       Impact factor: 5.742

8.  Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.

Authors:  Gopal Krishna; Malaz AbuTarif; Fengjuan Xuan; Monika Martinho; David Angulo; Oliver A Cornely
Journal:  Pharmacotherapy       Date:  2008-10       Impact factor: 4.705

9.  [Prevalence of malnutrition among candidates for lung transplantation].

Authors:  A J Calañas-Continente; C Cerveró Pluvins; E Muñoz Gomariz; R Lama Martínez; P Font Ugalde; M J Molina Puerta; F Santos Luna
Journal:  Nutr Hosp       Date:  2002 Jul-Aug       Impact factor: 1.057

10.  Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.

Authors:  Gopal Krishna; Monika Martinho; Pranatharthi Chandrasekar; Andrew J Ullmann; Hernando Patino
Journal:  Pharmacotherapy       Date:  2007-12       Impact factor: 4.705

View more
  27 in total

1.  Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.

Authors:  J J Vehreschild; C Müller; F Farowski; M J G T Vehreschild; O A Cornely; U Fuhr; K-A Kreuzer; M Hallek; V Kohl
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

2.  Plasma concentrations of posaconazole administered via nasogastric tube in patients in a surgical intensive care unit.

Authors:  Dominic Störzinger; Stephan Borghorst; Stefan Hofer; Cornelius J Busch; Christoph Lichtenstern; Georg Hempel; Markus A Weigand; Torsten Hoppe-Tichy
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

Review 3.  Antifungal stewardship considerations for adults and pediatrics.

Authors:  Rana F Hamdy; Theoklis E Zaoutis; Susan K Seo
Journal:  Virulence       Date:  2016-09-02       Impact factor: 5.882

4.  Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose.

Authors:  A Petitcollin; C Boglione-Kerrien; C Tron; S Nimubona; S Lalanne; F Lemaitre; E Bellissant; M-C Verdier
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

5.  Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.

Authors:  Jürgen Prattes; Wiebke Duettmann; Martin Hoenigl
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 6.  Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.

Authors:  Michael J Dolton; John E Ray; Deborah Marriott; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

7.  Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Authors:  Michael J Dolton; John E Ray; Sharon C-A Chen; Kingsley Ng; Lisa Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

8.  Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials.

Authors:  David Andes; Laura Kovanda; A Desai; Therese Kitt; M Zhao; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

Review 9.  Pharmacologic and clinical evaluation of posaconazole.

Authors:  Jason N Moore; Jason R Healy; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2015-05       Impact factor: 5.045

10.  Evaluation of Sulfobutylether-β-Cyclodextrin Exposure in a Critically Ill Patient Receiving Intravenous Posaconazole While Undergoing Continuous Venovenous Hemofiltration.

Authors:  Amanda A Morris; Scott W Mueller; Joseph E Rower; Taylor Washburn; Tyree H Kiser
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.